Calidi Biotherapeutics to Present RedTail Platform at H.C. Wainwright Global Investment Conference
TL;DR
Calidi Biotherapeutics' CEO presentation at the H.C. Wainwright conference highlights their RedTail platform's potential to deliver competitive advantages in treating metastatic cancers through systemic administration.
Calidi's RedTail platform uses engineered enveloped oncolytic viruses to shield from immune clearance, induce tumor lysis, and deliver genetic medicines to metastatic sites via systemic administration.
Calidi's innovative cancer therapy platform aims to improve treatment outcomes for patients with metastatic diseases, potentially making tomorrow better for those facing high unmet medical needs.
Calidi Biotherapeutics is pioneering systemic delivery of oncolytic viruses to target metastatic cancers, with their lead candidate currently in IND-enabling studies for multiple tumor types.
Found this article helpful?
Share it with your network and spread the knowledge!
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage immuno-oncology company, announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York. An on-demand presentation will be available starting September 5 at 7 a.m. ET, providing investors and industry stakeholders with detailed insights into the company's groundbreaking RedTail platform technology.
The presentation will focus on Calidi's proprietary RedTail platform, which represents a significant advancement in cancer treatment technology. This engineered enveloped oncolytic virus platform is specifically designed for systemic delivery and targeting of metastatic sites, addressing one of the most challenging aspects of cancer therapy. The platform's advanced enveloped technology is engineered to shield the virus from immune clearance, enabling virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations throughout the body.
Calidi's lead candidate from the RedTail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs. The company's approach could potentially transform cancer treatment by enabling systemic administration of genetic medicines to distal disease sites, overcoming limitations of current localized treatment methods. Additional information about the company's developments can be found at https://ibn.fm/CLDI.
The significance of this presentation extends beyond investor relations, as it highlights the potential impact on cancer treatment paradigms. The RedTail platform's ability to protect viruses from immune clearance while delivering therapeutic genetic medicines systemically addresses critical challenges in metastatic cancer treatment. This technology could lead to more effective treatments for patients with advanced cancers who currently have limited options. The conference presentation provides an opportunity for the medical and investment communities to understand how this innovative approach might change the landscape of oncology therapeutics and improve patient outcomes in hard-to-treat metastatic cancers.
Curated from InvestorBrandNetwork (IBN)
